Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy

Antiviral Therapy

Volumn 14, Issue 2, 2009, Pages 249-261

  Lai, Ming Wei ^a,b   Huang, Shiu Feng ^a,c   Hsu, Chao Wei ^a   Chang, Mei Hui ^a   Liaw, Yuin Faw ^a   Yeh, Chau Ting ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 1BETA CONVERTING ENZYME; LAMIVUDINE; TUMOR NECROSIS FACTOR ALPHA; RNA DIRECTED DNA POLYMERASE INHIBITOR; S ENVELOPE PROTEIN, HEPATITIS B VIRUS; VIRUS ENVELOPE PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; EXPRESSION VECTOR; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MOUSE; NONHUMAN; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; STOP CODON; TRANSACTIVATION; VIRUS CARCINOGENESIS; ANIMAL; CANCER TRANSPLANTATION; CELL STRAIN 3T3; DRUG EFFECT; GENETICS; LIVER TUMOR; MIDDLE AGED; VIROLOGY;

ADULT; ANIMALS; CARCINOMA, HEPATOCELLULAR; CODON, NONSENSE; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER NEOPLASMS; MALE; MICE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NIH 3T3 CELLS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL ENVELOPE PROTEINS;

EID: 67149139969     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88:8495-8499.
2. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-68.
3. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:1657-1661.
4. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997; 71:9392-9399.
5. Liaw YF, Leung NWY, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119:172-180.
6. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711-713.
7. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714-717.
8. Schalm SW. Clinical implications of lamivudine resistance by HBV. Lancet 1997; 349:3-4.
9. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816.
10. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126:91-101.
11. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48:747-755.
12. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31:1318-1326.
13. Karatayli E, Karayal&in S, Karaaslan H, et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007; 12:761-768.
14. Gerolami R, Bourliere M, Colson P, et al. Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Antivir Ther 2006; 11:1103-1106.
15. * mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48:88-98.
16. Kekule AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 1990; 343:457-461.
17. Lauer U, Weiss L, Hofschneider PH, Kekule AS. The hepatitis B virus pre-S/S(t) transactivator is generated by 3′ truncations within a defined region of the S gene. J Virol 1992; 66:5284-5289.
18. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
19. Das K, Xiong X, Yang H, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75:4771-4779.
20. Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264-273.
21. Melegari M, Bruno S, Wands JR. Properties of hepatitis B virus pre-S1 deletion mutants. Virology 1994; 199:292-300.
22. Fan YF, Lu CC, Chen WC, et al. Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 2001; 33:277-286.
23. Iwao K, Tsukamoto I. Quercetin inhibited DNA synthesis and induced apoptosis associated with increase in c-fos mRNA level and the upregulation of p21WAF1CIP1 mRNA and protein expression during liver regeneration after partial hepatectomy. Biochim Biophys Acta 1999; 1427:112-120.
24. Inada K, Okada S, Phuchareon J, et al. c-Fos induces apoptosis in germinal center B cells. J Immunol 1998; 161:3853-3861.
25. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31:207-210.
26. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33:301-307.
27. Koike K, Tsutsumi T, Fujie H, Shintani Y, Moriya K. Molecular mechanism of viral hepatocarcinogenesis. Oncology 2002; 62 Suppl 1:29-37.
28. Di Marco V, Di Stefano R, Ferraro D, et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther 2005; 10:431-439.
29. Andreone P, Gramenzi A, Cursaro C, et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 2004; 11:439-442.
30. Watari A, Takaki K, Higashiyama S, et al. Suppression of tumorigenicity but not anchorage independence, of human cancer cells by new candidate tumor suppressor gene CapG. Oncogene 2006; 25:7373-7380.
31. Thomassen DG, DeMara R. Clonal analysis of the stepwise appearance of anchorage independence and tumorigenicity in CAK, a permanent line of mouse cells. Cancer Res 1982; 42:4054-4063.